Stockscreener 앱 받기
27.19
2.19%
-0.61
시간 외 거래:
27.19
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 29.77% Potential Upside in Biotechnology - DirectorsTalk Interviews
Weekly Recap: How Agios Pharmaceuticals Inc. stock valuations compare to rivalsWatch List & Accurate Buy Signal Notifications - Bộ Nội Vụ
Sickle Cell Disease Treatment Market is Thriving Worldwide | - openPR.com
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
Ideas Watch: Is Agios Pharmaceuticals Inc stock good for income investorsJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval - Investing.com
Agios Pharmaceuticals Outlines 2026 Strategic Priorities and Milestones - TradingView — Track All Markets
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - The Manila Times
New anemia pill and sickle cell trials set up big year in rare disease care - Stock Titan
Published on: 2026-01-11 10:51:52 - Улправда
Peregrine Capital Management LLC Makes New $6.54 Million Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. stock performs in rate cut cycles2025 Big Picture & Technical Pattern Based Buy Signals - ulpravda.ru
Agios Pharmaceuticals plunges as Phase 3 sickle cell results deliver a mixed picture - MSN
(AGIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AGIO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
What Wall Street predicts for Agios Pharmaceuticals Inc. stock priceJuly 2025 Patterns & AI Forecasted Entry and Exit Points - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - Улправда
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - Улправда
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock By Investing.com - Investing.com India
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Here's why shares in Agios Pharmaceuticals popped today - MSN
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) t - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
JPMorgan Chase & Co. Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $25.00 - MarketBeat
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
How FDA Approval of First-in-Class Thalassemia Anemia Drug AQVESME Could Impact Agios Pharmaceuticals (AGIO) Investors - Sahm
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios pharma chief medical officer Gheuens sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals CEO Goff sells $506,663 in stock - Investing.com
Jones Cecilia, Agios Pharmaceuticals CFO, sells $79k in stock By Investing.com - Investing.com UK
Agios Pharma shares jump 16% as US FDA expands approval for blood disorder drug - MSN
Momentum Indicator Shows Bearish Divergence in Sylvan Plyboard India LimitedRisk-Reward Ratio Analysis & Stay Ahead With Daily Market Discussions - earlytimes.in
How Agios Pharmaceuticals Inc. stock valuations compare to rivalsStock Correlation Metrics & Free Superior Profit Margins - bollywoodhelpline.com
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - MSN
Geopolitics Watch: Is Agios Pharmaceuticals Inc 8AP stock attractive post correctionLayoff News & Low Risk Entry Point Tips - moha.gov.vn
4.73%
0.92%
자본화:
|
볼륨(24시간):